Small Molecules Targeting KLF5 and EGR1 in Colorectal Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for colorectal cancer (CRC) are often ineffective due to specific mutations and produce multiple side effects, and there is a lack of compounds that effectively target the WNT and KRAS signaling pathways implicated in CRC development and progression.
Innovation Solution
Development of a new small molecule lead, SR18662, which inhibits the growth of CRC cells by reducing the expression levels of KLF5 and EGR1, targeting the MAPK and WNT/β-catenin signaling pathways, and inducing apoptosis in CRC cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard chemotherapy treatments are used to inhibit DNA synthesis and transcription, then cancer cell growth is suppressed, but multiple side effects occur and treatment becomes ineffective due to specific mutations
Solution Approach 1:
The patent changes the therapeutic parameter from general DNA synthesis inhibition to specific transcription factor (KLF5 and EGR-1) suppression. This targeted parameter change allows effective cancer cell growth inhibition while reducing off-target effects on normal cells, thereby improving treatment reliability and reducing side effects simultaneously.
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that specifically bind to and suppress KLF5 and EGR-1 transcription factors. These intermediary molecules mediate the therapeutic effect by blocking the oncogenic signaling pathways without directly damaging DNA or affecting all rapidly dividing cells, thus reducing side effects while maintaining treatment effectiveness.
2Adaptability or versatility
If targeted therapies block VEGF, EGFR or other kinases, then specific signaling pathways are inhibited, but resistance develops due to mutations acquired during cancer progression
Solution Approach 1:
The patent extracts and targets the specific transcription factors (KLF5 and EGR-1) that are downstream effectors of multiple oncogenic pathways including WNT and KRAS. By taking out this common downstream node, the therapy can inhibit multiple parallel signaling pathways simultaneously, preventing cancer cells from developing resistance through single pathway mutations.
Solution Approach 2:
The small molecule compounds developed in the patent have multi-functional activity by simultaneously suppressing both KLF5 and EGR-1 transcription factors. This universal inhibition of multiple oncogenic drivers provides broader and more durable therapeutic coverage compared to single-target therapies, improving long-term efficacy.
3Reliability
If compounds are developed to target WNT and KRAS signaling pathways, then colorectal cancer development and progression are addressed, but no compounds have successfully progressed through clinical trials
Solution Approach 1:
The patent uses small molecule compounds as intermediaries that indirectly target WNT and KRAS pathways by suppressing their downstream transcription factors (KLF5 and EGR-1). This intermediary approach bypasses the technical challenges of directly targeting constitutively active WNT/KRAS pathways, simplifying compound development while maintaining reliable cancer progression inhibition.
Data Source
AI summary
The present disclosure provides compounds of formula (I), as described herein, their pharmaceutically acceptable salts, and their pharmaceutical compositions, which are effective in reducing the expression level of KLF5 or EGR1 in a living cell, and for the treatment of tumors and colorectal cancer in a human patient.